These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27575023)

  • 21. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
    Huang KT; Mikeska T; Li J; Takano EA; Millar EK; Graham PH; Boyle SE; Campbell IG; Speed TP; Dobrovic A; Fox SB
    BMC Cancer; 2015 Oct; 15():669. PubMed ID: 26452468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of PET-CT in detecting unknown primary tumour in patients with cervical lymph node metastases].
    Fülöp M; Kásler M; Remenár E; Lengyel Z; Borbély K
    Magy Onkol; 2012 May; 56(2):84-92. PubMed ID: 22629545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
    Staub E; Buhr HJ; Gröne J
    Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.
    Sherwood J; Dearden S; Ratcliffe M; Walker J
    J Exp Clin Cancer Res; 2015 Sep; 34(1):92. PubMed ID: 26338018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
    Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular diagnostic methods designed for clinical approach to cancer of unknown origin].
    Fujita Y; Nishio K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):923-6. PubMed ID: 19542713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
    Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
    Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
    Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer of unknown primary site: evolving understanding and management of patients.
    Greco FA
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
    Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
    Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
    Vikeså J; Møller AK; Kaczkowski B; Borup R; Winther O; Henao R; Krogh A; Perell K; Jensen F; Daugaard G; Nielsen FC
    BMC Cancer; 2015 Mar; 15():151. PubMed ID: 25885340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.